RAMM Pharma Past Earnings Performance
Past criteria checks 0/6
RAMM Pharma's earnings have been declining at an average annual rate of -19.7%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 3.3% per year.
Key information
-19.7%
Earnings growth rate
-2.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 3.3% |
| Return on equity | -30.1% |
| Net Margin | -177.9% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How RAMM Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 5 | -8 | 7 | 0 |
| 31 Oct 23 | 5 | -8 | 7 | 0 |
| 31 Jul 23 | 5 | -20 | 9 | 0 |
| 30 Apr 23 | 5 | -20 | 8 | 0 |
| 31 Jan 23 | 4 | -21 | 8 | 0 |
| 31 Oct 22 | 4 | -21 | 8 | 0 |
| 31 Jul 22 | 4 | -7 | 7 | 0 |
| 30 Apr 22 | 4 | -9 | 8 | 0 |
| 31 Jan 22 | 4 | -8 | 7 | 0 |
| 31 Oct 21 | 4 | -7 | 7 | 0 |
| 31 Jul 21 | 4 | -7 | 7 | 0 |
| 30 Apr 21 | 4 | -6 | 7 | 0 |
| 31 Jan 21 | 5 | -7 | 8 | 0 |
| 31 Oct 20 | 5 | -7 | 9 | 0 |
| 31 Jul 20 | 6 | -10 | 7 | 0 |
| 30 Apr 20 | 6 | -9 | 6 | 0 |
| 31 Jan 20 | 5 | -9 | 4 | 0 |
| 31 Oct 19 | 6 | -7 | 3 | 0 |
| 31 Oct 18 | 8 | -1 | 2 | 0 |
Quality Earnings: RAMM is currently unprofitable.
Growing Profit Margin: RAMM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RAMM is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare RAMM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAMM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.4%).
Return on Equity
High ROE: RAMM has a negative Return on Equity (-30.1%), as it is currently unprofitable.